Letters Angiotensin receptor blockers

Fraudulent data: an apology and the fate of angiotensin receptor blockers

BMJ 2013; 347 doi: https://doi.org/10.1136/bmj.f5549 (Published 18 September 2013) Cite this as: BMJ 2013;347:f5549
  1. Sripal Bangalore, assistant professor of medicine1,
  2. Franz H Messerli, director of hypertension programme2
  1. 1Leon H Charney Division of Cardiology, New York University School of Medicine, New York, NY 10016, USA
  2. 2St Luke’s Roosevelt Hospital and Columbia University, New York, NY, USA
  1. sripalbangalore{at}gmail.com

Controversy has recently surfaced over the data integrity of two large trials of the angiotensin receptor blocker (ARB) valsartan. The unblinded Kyoto heart study,1 for which we were invited to write an editorial, reported a 45% reduction in primary outcomes with valsartan, driven by a surprising 49% reduction in angina and 45% reduction in stroke.1 The near halving of stroke rate despite no changes in blood pressure was touted as a blood pressure independent effect. Like the double …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe